Since the treatment of colon cancer cell lines with patritumab down-regulates PI3K signaling but results in the activation of MAPK pathway as a compensatory mechanism, we decided to test the effect induced by the MEK-inhibitor trametinib. This evidence concerns the gene PIK3CA and malignant colon neoplasm.